"Raw Rank","Signature group","All Patients (No. of Events)<br />Training dataset","12-months Survival Probability (%, 95% Cl)<br />Training dataset","36-months Survival Probability (%, 95% Cl)<br />Training dataset","60-months Survival Probability (%, 95% Cl)<br />Training dataset","All Patients (No. of Events)<br />ProLT_stageIII","12-months Survival Probability (%, 95% Cl)<br />ProLT_stageIII","36-months Survival Probability (%, 95% Cl)<br />ProLT_stageIII","60-months Survival Probability (%, 95% Cl)<br />ProLT_stageIII","All Patients (No. of Events)<br />ProV_stageII","12-months Survival Probability (%, 95% Cl)<br />ProV_stageII","36-months Survival Probability (%, 95% Cl)<br />ProV_stageII","60-months Survival Probability (%, 95% Cl)<br />ProV_stageII","All Patients (No. of Events)<br />ProV_stageIII","12-months Survival Probability (%, 95% Cl)<br />ProV_stageIII","36-months Survival Probability (%, 95% Cl)<br />ProV_stageIII","60-months Survival Probability (%, 95% Cl)<br />ProV_stageIII"
1,"High risk","23 (18)","82.61 (68.48 - 99.65)","39.13 (23.5 - 65.14)","22.01 (9.31 - 52.03)","24 (12)","69.57 (53.09 - 91.16)","46.25 (29.37 - 72.81)","46.25 (29.37 - 72.81)","76 (11)","98.65 (96.05 - 100)","85.44 (77.46 - 94.23)","85.44 (77.46 - 94.23)","80 (25)","89.39 (82.7 - 96.62)","71.69 (61.83 - 83.11)","66.55 (56.13 - 78.9)"
2,"Low risk","73 (12)","95.89 (91.44 - 100)","89.04 (82.16 - 96.5)","83.71 (75.23 - 93.15)","52 (25)","80.52 (70.38 - 92.13)","54.99 (42.9 - 70.49)","52.49 (40.29 - 68.38)","32 (3)","96.43 (89.79 - 100)","91.84 (81.51 - 100)","87 (74.17 - 100)","30 (12)","80 (66.89 - 95.67)","72.88 (58.44 - 90.88)","52.87 (33.29 - 83.96)"
